Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AK105 + carboplatin + pemetrexed
- Development stage
- Discontinued
- Lead developer
- Kangfang Sainuo Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a **combination regimen** comprising AK105 (also known as penpulimab), carboplatin, and pemetrexed. AK105/penpulimab is a human IgG1 monoclonal antibody targeting PD-1, designed with Fc mutations to eliminate Fc receptor and complement-mediated effector functions, thus preventing antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Carboplatin is a platinum-based chemotherapeutic agent that causes DNA crosslinking and apoptosis, while pemetrexed is an antifolate that disrupts thymidylate synthesis, inhibiting DNA and RNA synthesis. This combination is under investigation as an antineoplastic regimen, particularly for solid tumors.
- Other names
- penpulimab + carboplatin + pemetrexed
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)
Beyond the preview
Go deeper on AK105 + carboplatin + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AK105 + carboplatin + pemetrexed.